Endonovo Therapeutics Total Liabilities

Endonovo Therapeutics (ENDV) currently reports a total liabilities of $30M as of June 2026. That compares with $28M in the prior-year period — up 8.1% year over year. Use the charts on this page to explore Endonovo Therapeutics's total liabilities history and peer comparisons.

Endonovo Therapeutics's total liabilities increased from $28M to $30M — a 8.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Endonovo Therapeutics reported $30M in total liabilities as of June 2026. That compares with $28M in the prior-year period — up 8.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $30M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Endonovo Therapeutics, and consider following ENDV for alerts when major investors trade the stock.

Endonovo Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $30M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENDV with unrelated industries.